Inactive Instrument

Highlights Vyant Bio, Inc.

Equities

VYNT

US92942V2088

Highlights

Unlock all the news: Be the first to know and act before the market!

Vyant Bio, Inc. Estimates Liquidation Payments to its Shareholders	Nov. 10	CI
Vyant Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Vyant Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-07-31	CI
AxoSim, Inc. entered into an agreement to acquire microBrain?-associated assets from Vyant Bio, Inc. for $3.5 million.	23-07-16	CI
Vyant Bio to Voluntarily Delist From Nasdaq, Deregister From SEC; Shares Slide After Hours	23-04-24	MT
Vyant Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Earnings Flash (VYNT) VYANT BIO Reports Q3 Revenue $152,000	22-11-15	MT
Vyant Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Vyant Bio, Inc. to Participate at Neuroscience 2022, the 52nd Annual Gathering of the Society for Neuroscience, on November 12-16, 2022	22-11-10	CI
Reaction Biology Corporation acquired vivoPharm, LLC from Vyant Bio, Inc. for approximately $6 million.	22-11-02	CI
Reverse Split: 1 of 5	22-11-01	FA
Earnings Flash (VYNT) VYANT BIO Posts Q2 Revenue $165,000, vs. Street Est of $0.2M	22-08-22	MT
Vyant Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-22	CI
Earnings Flash (VYNT) VYANT BIO Posts Q1 Revenue $303,000	22-05-16	MT
Vyant Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Earnings Flash (VYNT) VYANT BIO Posts Q4 Revenue $1.15M	22-03-30	MT
Vyant Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
Vyant Bio, OrganoTherapeutics Enter Into Drug Discovery Collaboration for Parkinson's Disease; Vyant Bio Shares Surge Pre-Bell	22-03-30	MT
Vyant Bio, Inc. and OrganoTherapeutics Announce Strategic Collaboration to Discover Therapeutics to Treat Parkinson’s Disease	22-03-29	CI
Earnings Flash (VYNT) VYANT BIO Reports Q3 Revenue $1.51M	21-11-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vyant Bio, Inc.

Equities

VYNT

US92942V2088

Highlights

Filters